A substantial proportion of people with diabetic peripheral neuropathy experience neuropathic pain, typically described as burning, stabbing, or electric-shock sensations that are worse at night. Painful diabetic peripheral neuropathy (pDPN) disrupts sleep, mood, and mobility, and it often coexists with the sensory loss that places the foot at risk for ulceration. Choosing among the many available treatments requires understanding what randomized evidence does, and does not, support.
First-Line Systemic Medications
Guidance has been consistent on the core drug classes. The Neuropathic Pain Special Interest Group (NeuPSIG) systematic review and meta-analysis by Finnerup and colleagues (Lancet Neurology, 2015) gave strong recommendations for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors (SNRIs such as duloxetine), and gabapentinoids (gabapentin and pregabalin) as first-line options for neuropathic pain generally. The American Diabetes Association position statement by Pop-Busui and colleagues (Diabetes Care, 2017) similarly recommends pregabalin or duloxetine as initial pharmacologic choices in diabetes and advises against opioids, including tapentadol, as first- or second-line therapy because of addiction and safety concerns.
What Pooled Trials Show
A 2021 meta-analysis by Lian, Ma, and Fu (Frontiers in Neurology) pooled 37 randomized trials of drugs for pDPN. Pregabalin, duloxetine, and tapentadol produced significant pain reductions versus placebo. For at least 50% pain reduction, the relative risks were about 1.32 for pregabalin, 1.43 for duloxetine, and 1.38 for tapentadol. Gabapentin did not reach statistical significance in the pooled trials, although the evidence base for it is smaller and heterogeneous. Adverse events were more frequent than with placebo for pregabalin (somnolence, dizziness, peripheral edema), duloxetine (nausea, somnolence), and tapentadol (nausea, vomiting, and addiction risk). The authors noted that most trials lasted under three months and that overall evidence quality was low, so long-term comparative effectiveness remains uncertain.
Topical Therapy: High-Concentration Capsaicin
Topical approaches avoid many systemic side effects. The Cochrane review by Derry and colleagues (2017) on high-concentration (8%) capsaicin patches found moderate-quality evidence of benefit in postherpetic neuralgia, with a number needed to treat of roughly 7 to 9 for being “much or very much improved.” For painful diabetic neuropathy, only one study of 369 participants was available; about 10% more participants on capsaicin than on control reported substantial improvement, but the reviewers rated this evidence as very low quality. Local burning and redness were common and usually brief, and serious adverse events were similar between groups (3.5% versus 3.2%). NeuPSIG gave capsaicin 8% a weak recommendation as a later-line option. Topical therapy may therefore suit patients who cannot tolerate oral agents, though the diabetes-specific evidence is limited.
Neuromodulation for Refractory Pain
For pain that persists despite medications, spinal cord stimulation has been tested in a randomized trial. Petersen and colleagues (JAMA Neurology, 2021) reported the SENZA-PDN trial, which randomized 216 participants at 18 U.S. centers to 10 kHz spinal cord stimulation plus conventional medical management or to conventional management alone. At six months, 85% of the stimulation group achieved more than 50% pain relief, compared with 5% of the control group, with mean pain reduction of 76% versus 2%. Two of 90 permanent implants (2.2%) were explanted for infection, and wound complications occurred in 5.6%. Limitations include the absence of blinding, the industry-sponsored design, and the need for longer follow-up and independent replication. Because device implantation carries procedural risk, it is generally reserved for carefully selected patients with refractory symptoms after specialist evaluation.
Clinical Considerations
Pain relief in pDPN is usually partial; a 30% to 50% reduction is considered meaningful. Treatment selection typically weighs comorbidities, renal function, concurrent medications, fall risk, and side-effect tolerability. Importantly, pain-modifying drugs do not alter the underlying nerve damage or restore protective sensation. Painful neuropathy can also coexist with, and mask, a progressively insensate foot, so regular foot examination and risk stratification remain necessary regardless of symptom control. Optimizing glycemic control, addressing cardiovascular risk factors, and screening for contributors such as B12 deficiency complement symptomatic therapy.
Key Takeaways
Pregabalin and duloxetine have the most consistent randomized support for painful diabetic neuropathy, and guideline bodies advise against opioids as routine therapy. High-concentration capsaicin has modest, low-certainty evidence specific to diabetes. High-frequency spinal cord stimulation showed large benefits in an unblinded randomized trial for refractory pain, pending longer-term confirmation. Across all options, trials are short, and evidence certainty is generally low to moderate.
References
- Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015.
- Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017.
- Lian J, Ma L, Fu J. Different drugs for the treatment of painful diabetic peripheral neuropathy: a meta-analysis. Front Neurol. 2021.
- Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017.
- Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol. 2021.
Comments
